HemaCare (OTCMKTS:HEMA) Trading Up 0.6% – Should You Buy?

HemaCare Co. (OTCMKTS:HEMAGet Free Report)’s share price rose 0.6% on Wednesday . The company traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares changed hands during trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.

HemaCare Trading Up 0.6 %

The company’s 50-day simple moving average is $25.31 and its 200 day simple moving average is $25.31.

HemaCare Company Profile

(Get Free Report)

HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.

Featured Stories

Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.